Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Experimental diabetes treatment helps Chicago woman go off insulin

Key Takeaway: An experimental diabetes treatment has enabled a Chicago woman to discontinue her insulin use, showcasing the potential benefits of the new therapy. This advancement highlights the ongoing efforts in diabetes management and the transformative impact of innovative treatments on patients' lives. The treatment's success could pave the way for further clinical trials and research in diabetes care.
Price reaction · baseline $4.07 (2024-11-14T16:39:00.000Z) · hit during market hours · 3 other ELDN headline(s) in the window, move may be shared
day 0 close · peak
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • The treatment has led to significant improvements in patient health.
  • A Chicago woman was able to stop using insulin after the treatment.
  • The experimental drug shows promise in managing diabetes effectively.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the new diabetes treatment mentioned?

The article discusses an experimental diabetes treatment that has shown promising results.

How did the treatment affect the Chicago woman?

The treatment enabled her to stop using insulin, significantly improving her health.

What are the implications of this treatment?

This treatment could lead to further research and clinical trials in diabetes management.

Is the treatment widely available?

The treatment is still experimental and not yet widely available to the public.

Last updated: Nov 14, 2024